CRM Publications

CRM NCBI Bibliography


  1. Almahariq MF, Quinn TJ, Kesarwani P, Kant S, Miller CR, Chinnaiyan P.  Inhibition of colony-stimulating factor-1 receptor enhances the efficacy of radiotherapy and reduces immune suppression in glioblastoma.  In Vivo.  35(1):119-129 Jan-Feb 2021. PMID: 33402457


  1. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Ngan CY, Chapman M, Koehler JW, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH, Woolard KD, Heimberger AB, Levine JM, Verhaak RGW.  Comparative molecular life history of spontaneous canine and human gliomas.  Cancer Cell.  37(2):243-257 Feb 2020.  PMID: 32049048 PMCID: PMC7132629
  2. Buckley A, Hagler SB, Lettry V, Bago JR, Maingi SM, Khagi S, Ewend MG, Miller CR, Hingtgen SD.  Generation and profiling of tumor-homing induced neural stem cells from the skin of cancer patients.  Molecular Therapy.  28(7):1614-1627 Apr 2020.  PMID: 32402245  PMCID: PMC7132629
  3. Su YT, Butler M, Yu G, Zhang M, Zhang W, Hwang L, Tran AD, Bash RE, Schorzman AN, Zamboni WC, Wang X, Frye SV, Miller CR, Maric D, Terabe M, Gilbert MR, Earp HS, Wu J.  MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.  Neuro-oncology Advances.  2(1):vdaa065 June 2020.  PMID: 32642716  PMCID: PMC7324055
  4. Gawley M, Almond L, Daniel S, Lastakchi S, Kaur S, Detta A, Cruickshank G, Miller R, Hingtgen S, Sheets K, McConville C.  Development and in vivo evaluation of irinotecan-loaded drug eluting seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.  Journal of Controlled Release.  324:1-16 Aug 2020.  PMID: 32407745
  5. Skinner KR, Nabors LB, Miller CR.  Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.  Neuro-oncology.  22(12):1713-1714 Dec 2020. PMID: 33257985  PMCID: PMC7746940


  1. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Ngan CY, Chapman M, Koehler JW, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer R, Taylor AR, Rossmeisl JH, Heimberger A, Levine JM, Verhaak RGW.  Comparative molecular life history of spontaneous canine and human gliomas.  bioRxiv.  Jun 2019.  DOI: 10.1101/673822
  2. Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.  Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.  Neuro-oncology.  21(7):837-853 Jul 2019.  PMID: 30757579  PMCID: PMC6620638
  3. Zhang X, Kiapour N, Kapoor S, Khan T, Thamilarasan M, Tao Y, Cohen S, Miller R, Sobel RA, Markovic-Plese S.  IL-11 induces encephalitogenic Th17 cells in multiple sclerosis and experimental autoimmune encephalomyelitis.  Journal of Immunology.  203(5):1142-1150 Sep 2019.  PMID: 31341075
    PMCID: PMC6697738
  4. Miller AD, Miller CR, Rossmeisl JH.  Canine primary intracranial cancer: A clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors.  Frontiers in Oncology.  9:1151 Nov 2019.  PMID: 31788444  PMCID: PMC6856054


  1. Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O’Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma.  Journal of Neuropathology and Experimental Neurology.  77(11):1039-1054 Nov 2018.  PMID: 30239918  PMCID: PMC6181180  *Contributed equally
  2. Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Puhalla S, Abramson V, Carey LA, Anders CK.  LCCC 1025: A phase II study of everolimus, trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.  Breast Cancer Research and Treatment.  171(3):637-648 Oct 2018.  PMID: 29938395
  3. Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, Wilson G, Miller CR, Chinnaiyan P. Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research.  24(15):3632-3643 Aug 2018.  PMID: 29691296
  4. Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dimitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD.  Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.  PLoS One.  13(7):e0198596 Jul 2018.  PMID: 29990322 PMCID: PMC6038981
  5. McNeill RSStroobant EESmithberger ECanoutas DAButler MKShelton AKPatel SD, Limas JC, Skinner KRBash RESchmid RSMiller CR.  PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.  PLoS One.  13(7):e0200014 Jul 2018.  PMID: 29975751  PMCID: PMC6033446
  6. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY, Alliance for Clinical Trials in Oncology and Adult Brain Tumor Consortium (ABTC). Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: Results of Alliance N0874/ABTC 02.  Neuro-oncology.  20(4):546-556 Mar 2018.  PMID: 29016887  PMCID:  PMC5909661
  7. Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.  Nature Communications.  9(1):1057 Mar 2018.  PMID: 29535300  PMCID:  PMC5849741
  8. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen S, Ainslie KM. Sustained delivery of doxorubicin via acetalated dextran scaffold prevents glioblastoma recurrence after surgical resection.  Molecular Pharmaceutics.  15(3):1309-1318 Mar  PMID: 29342360  PMCID:  PMC5999333
  9. Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O’Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA. Frequency of breast cancer subtypes among African American women in the AMBER consortium.  Breast Cancer Research.  20(1):12 Feb 2018.  PMID: 29409530  PMCID: PMC5801839
  10. Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.  Scientific Reports.  8(1):1180 Jan 2018.  PMID: 29352201  PMCID: PMC5775420
  11. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. MerTK as a therapeutic target in glioblastoma.  Neuro-oncology. 20(1):92-102 Jan 2018.  PMID: 28605477  PMCID:  PMC5761530


  1. Khagi S, Miller CR. Putting “multiforme” back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.  Neuro-oncology.  Neuro-oncology.  19(12):1570-1571 Nov 2017.  PMID: 29016836  PMCID: PMC5716077
  2. McNeill RSCanoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DMBash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-oncology. 19(11):1469-1480 Oct 2017. PMID: 28379424  PMCID:  PMC5737415
  3. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.  Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  Neuro-oncology.  19(11):1481-1493 Oct 2017.  PMID: 28486691  PMCID:  PMC5737524
  4. Madden AJ, Oberhardt B, Lockney D, Santos C, Vennam P, Arney D, Franzen S, Lommel SA, Miller CR, Gehrig P, Zamboni WC. Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. Nanomedicine. 12(20):2519-2532 Oct 2017.  PMID: 28952882
  5. Vitucci M*, Irvin DM*, McNeill RSSchmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AMBash RE, Kim S, Berens ME, Miller CR.  Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  Neuro-oncology.  19(9):1237-1257 Sep 2017.  *Co-first authors.  PMID: 28398584  PMCID:  PMC5570221
  6. Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. American Journal of Clinical Pathology. 148(2):108-118 Aug 2017. PMID: 28898983  PMCID:  PMC5848430
  7. Stowe HB, Miller CRWu J, Randazzo DM, Ju AW. Pineal region glioblastoma, a case report and literature review. Frontiers in Oncology. 7:123 Jun 2017. PMID: 28660172  PMCID: PMC5466962
  8. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9(391) May 2017. PMID: 28539475
  9. Bago JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Vander Werff R, Underhill TM, Schmid RSMiller CR, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9(375):eaah6510 Feb 2017. PMID: 28148846
  10. Irvin DMMcNeill RSBash REMiller CR. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology. 27(1):36-50 Jan 2017. PMID: 26762242  PMCID:  PMC5322824
  11. Kaiser-Rogers K, Trembath D, Miller CR.  In situ hybridization.  In:  Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier, 2017.  Pages 1-7.  ISBN 978-0-128-09324-5


  1. Okolie O, Bago JR, Schmid RSIrvin DMBash RE, Miller CR*, Hingtgen SD*.  Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.  Neuro-oncology.  18(12):1622-1633 Dec 2016.  *Co-senior authors  PMID: 27298311  PMCID: PMC5791515
  2. Hu P, Li Y, Nikolaishvili-Feinberg N, Scesa G, Bi Y, Pan D, Moore D, Bongarzone ER, Sands MS, Miller R, Kafri T. Hematopoietic stem cell transplantation and lentiviral vector-based gene therapy for Krabbe’s disease: Present convictions and future prospects. Journal of Neuroscience Research. 94(11):1152-1168 Nov 2016. PMID:  27638600  PMCID:  PMC5027985
  3. McNeill RSIrvin DMMiller CR.  BRAF mutations open doors to ENU-induced gliomagenesis.  American Journal of Pathology.  186(10):2551-2554 Oct 2016.  PMID: 27543966  PMCID: PMC5222976
  4. LeBlanc AK, Mazcko C, Brown DB, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau B, Levine JM, Simpson MR, Halsey C, Kisseberth W, Rossmeisl JH, Dickinson PJ, Fan T, Corps K, Aldape K, Puduvalli V, Gilbert MR.  Creation of an NCI Comparative Brain Tumor Consortium: Informing the translation of new knowledge from canine to human brain tumor patients.  Neuro-oncology.  18(9):1209-1218 Sep 2016.  PMID: 27179361  PMCID: PMC4999002
  5. Schmid RS, Simon JM, Vitucci MMcNeill RSBash REWerneke AMHuey LWhite KK, Ewend MG, Wu JMiller CR.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.  Neuro-oncology.  18(7):962-973 Jul 2016.  PMID: 26826202  PMCID: PMC4896545
  6. Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli G, Miller CR, Hwang H, Thorne L, O’Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea T, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.  Performance of three biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium.  Cancer Epidemiology, Biomarkers & Prevention.  25(3):470-478 Mar 2016.  PMID: 26711328  PMCID: PMC4779705
  7. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS, Miller CR, Magness ST, Hingtgen SD.  Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma.  Nature Communications.  7:10593 Feb 2016.  PMID: 26830441 PMCID: PMC4740908
  8. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao A, Grifford M, Cherniack AD, Zhang H, Poisson L, Rao A, Mikkelsen T, Lau CC, Yung WKA, Rabadan R, Huse J, Brat DJ, Lehman N, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Cancer Genome Atlas Research Network, Noushmehr H, Iavarone A, Verhaak RGW.  Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.  Cell.  164(3):550-563 Jan 2016.  PMID: 26824661  PMCID: PMC4754110


  1. Prabhu A, Sarcar B, Miller CR, Kim SH,Nakano I, Forsyth P, Chinnaiyan P.  Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.  Neuro-oncology.  17(9):1220-1230 Sep 2015.  PMID: 25712957  PMCID: PMC4588752
  2. Garcia I, Crowther AJ, Gama V, Miller CR, Deshmukh M, Gershon TR.  Erratum: Bax-deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation.  Oncogene.  34(29):3881 Jul 2015.  PMID:  26179456
  3. Cancer Genome Atlas Research Network.  Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.  New England Journal of Medicine.  372(26):2481-2498.  Jun 2015.  PMID: 26061751  PMCID: PMC4530011
  4. Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikoliashvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.  IL-2 inducible T-cell kinase, a novel therapeutic target in melanoma.  Clinical Cancer Research.  21(9):2167-2176 May 2015.  PMID: 25934889  PMCID: PMC4418029
  5. Karginova O, Siegel MB, Adamo B, Deal AM, Van Swearingen AED, Nikolaishvili-Feinberg N, Parker JS, Santos CM, Darr D, Bash R, Sandison K, Zamboni WC, Miller CR, Anders CK.  Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple negative breast cancer.  Molecular Cancer Therapeutics.  14(4):920-930 Apr 2015. PMID: 25824335  PMCID: PMC4394032
  6. Knight ER, Patel EY, Flowers CA, Crowther AJ, Ting JP, Miller CR, Gershon TR, Deshmukh M.  ASC deficiency suppresses proliferation and prevents medulloblastoma incidence.  Oncogene.  34(3):394-402 Jan 2015.  PMID: 24469054  PMCID: PMC4520702
  7. McNeill RSVitucci MWu JMiller CR.  Contemporary murine models in preclinical astrocytoma drug development.  Neuro-oncology.  17(1):12-28 Jan 2015.  PMID: 25246428  PMCID: PMC4483055


  1. Song G, Darr D, Santos CM, Ross M, Valdivia A, Jordan J, Midkiff BR, Cohen SM, Feinberg NN, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC.  Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.  Clinical Cancer Research.  20(23):6083-6095 Dec 2014.  PMID: 25231403  PMCID: PMC4565518
  2. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, Verhaak RGW, Nishiyama A, Miller CR, Zong H.  Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multi-step reactivation process.  Proceedings of the National Academy of Science USA.  111(40):E4214-E4223 Oct 2014.  PMID: 25246577  PMCID: PMC4210043
  3. McNeill RSSchmid RSBash REVitucci MWhite KKWerneke AMConstance BHHuff BMiller CR.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.  Journal of Visualized Experiments.  90:e51763 Aug 2014.  PMID: 25146643.
  4. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.  European Urology.  66(1):77-84 Jul 2014.  PMID: 24613583  PMCID: PMC4058355
  5. Nikolaishvilli-Feinberg N, Cohen SM, Midkiff B, Zhou Y, Olorvida M, Ibrahim JG, Omolo B, Shields JM, Thomas NE, Groben PA, Kaufmann WK, Miller CR.  Development of DNA damage response signaling biomarkers using automated, quantitative image analysis.  Journal of Histochemistry and Cytochemistry.  62(3):185-196 Mar 2014.  PMID: 24309508  PMCID: PMC3935445
  6. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, Perou CM, Levine RL, Diehn M, Kim WY.  Erythropoietin promotes breast cancer tumorigenesis through tumor initiating cell self-renewal.  Journal of Clinical Investigation.  124(2):553-563 Feb 2014.  PMID: 24435044  PMCID: PMC3904607
  7. Malin D, Strekalova E, Petrovic V, Deal AM, Ahmad AA, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton EP, Blackwell K, Geradts J, Ewend M, Carey LA, Shusta EV, Anders CK, Cryns VL.  αB-crystallin: A novel regulator of breast cancer metastasis to the brain.  Clinical Cancer Research.  20(1):56-67 Jan 2014:  PMID: 24132917  PMCID: PMC3973485
  8. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.  Where are we now?  And where are we going?  A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma workshop.  Neuro-oncology.  16(2):173-178 Jan 2014.  PMID: 24305708  PMCID: PMC3895389
  9. Kaiser-Rogers C, Trembath D, Miller CR.  In situ hybridization.  In:  Aminoff MJ and Dardoff RB (eds), Encyclopedia of Neurological Sciences, 2nd Ed., Vol. 2, Oxford: Academic Press, 2014.  Chapter 593. Pages 699-704.  ISBN 978-0-123-85157-4


  1. Huff LP, DeCristo MJ, Trembath D, Kuan PF, Yim M, Liu J, Cook DR, Miller CR, Der CJ, Cox AD.  The role of Ect2 nuclear RhoGEF activity in ovarian cancer cell transformation.  Genes & Cancer.  4(11-12):460-475 Nov/Dec 2013.  PMID: 24386507  PMCID: PMC3877668
  2. Kimura M, Lee Y, Miller R, Castillo M.  Glioblastoma multiforme: relationship to subventricular zone and recurrence.  Neuroradiology Journal. 26(5):542-547 Oct 2013.  PMID: 24199814  PMCID: PMC4202832
  3. Song Y, Zhang Q, Kutlu B, Difilippantonio S, Bash R, Gilbert D, Yin C, O’Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN, Miller CR, Hood L, Van Dyke T.  Evolutionary etiology of high-grade astrocytomas.  Proceedings of the National Academy of Science USA.  110(44):17933-17938 Oct 2013.  PMID: 24114272 PMCID: PMC3816471
  4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, and Cancer Genome Atlas Research Network.  The somatic genomic landscape of glioblastoma.  Cell.  155(2):462-477 Oct 2013.  PMID: 24120142  PMCID: PMC3910500
  5. Vitucci M*, Karpinich NO*, Bash REWerneke AMSchmid RSWhite KKMcNeill RSHuff B, Wang S, Van Dyke T, Miller CR.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  *Co-first authors.  Neuro-oncology.  15(10):1317-1329 Oct 2013.  PMID: 23814263  PMCID: PMC3779038
  6. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper L, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE, Lehman NL, Miller CR, Schniederjan MJ, Brennan CW, Moreno CS, Staltz JH, Brat DJ.  Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.  Clinical Cancer Research.  19(18):4951-4960 Sep 2013.  PMID: 23864165  PMCID: PMC3865611
  7. Raghunathan A, Wani K, Armstrong TS, Ver-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD, Collaborative Ependymoma Research Network.  Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.  Brain Pathology.  23(5):584-594 Sep 2013.  PMID: 23452038
  8. Wilkerson MD*, Schallheim JM*, Hayes DN*, Roberts PJ, Bastein R, Mullins M, Yin X, Miller CR, Thorne LB, Funkhouser WK, Fan C, Hayward MC, Bayer S, Perou CM, Bernard PS.  Prediction of lung cancer histological types by qRT-PCR gene expression in FFPE specimens.  *Co-first authors.  Journal of Molecular Diagnostics.  15(4):485-497 Jul 2013.  PMID: 23701907  PMCID: PMC3699698
  9. Gershon TR, Crowther AJ, Liu H, Miller CR, Deshmukh M.  Cerebellar granule neuron progenitors are the source of Hk2 in the postnatal cerebellum.  Cancer and Metabolism.  1(1):15 Jun 2013.  PMID: 24280296  PMCID: PMC4178205
  10. Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Walsh M, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC.  Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer.  PLoS One.  8(5): e61359 May 2013.  PMID: 23650496  PMCID: PMC3641071
  11. Garcia I, Crowther AJ, Gama V, Miller CR, Deshmukh M, Gershon TR.  Bax-deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation.  Oncogene.  32(18):2304-2314 May 2013.  PMID:  22710714  PMCID: PMC3449008
  12. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.  MERTK receptor tyrosine kinase is a therapeutic target in melanoma.  Journal of Clinical Investigation.  123(5):2257-2267 Apr 2013.  PMID: 23585477  PMCID: PMC3639697
  13. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O’Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY.  HIF1α and HIF2α independently activate SRC to promote melanoma metastases.  Journal of Clinical Investigation.  123(5):2078-2093 Apr 2013.  PMID: 23563312  PMCID: PMC3635738
  14. Di L, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, Raab R, Olopade OI, Gardner K.  Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.  Nature Communications.  4:1449 Mar 2013.  PMID: 23385593  PMCID: PMC3768144
  15. Gershon TR, Crowther AJ, Tikunov A, Garcia I, Annis R, Yuan H, Miller CR, Macdonald J, Olson J, Deshmukh M.  Hexokinase-2 mediated aerobic glycolysis is integral to cerebellar neurogenesis and required for pathogenesis of medulloblastoma.  Cancer and Metabolism.  1(1):2 Jan 2013.  PMID: 24280485  PMCID: PMC3782751
  16. Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK.  Validation of interobserver agreement in lung cancer assessment: hematoxylin and eosin diagnostic reproducibility for non-small cell lung cancer – The 2004 World Health Organization classification and therapeutically relevant subsets.  Archives of Pathology & Laboratory Medicine.  137(1):32-40 Jan 2013.  PMID:  22583114


  1. Dellon ES, Chen X, Miller CR, Woosley JT, Shaheen NJ.  Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis.  American Journal of Gastroenterology.  107(10):1503-1511 Oct 2012.  PMID:  22777338  PMCID: PMC3744826
  2. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE.  LKB1/STK11 inactivation leads to expansion of a pro-metastatic tumor sub-population in melanoma.  Cancer Cell.  21(2):751-764 Jun 2012.  PMID:  22698401  PMCID: PMC3660964
  3. Schmid RS, Vitucci M, Miller CR.  Genetically engineered mouse models of diffuse gliomas.  Brain Research Bulletin.  88(1):72-79 May 2012.  PMID: 21684324
  4. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, Perou CM, Hayes DN.  Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.  PLoS One.  7(5):e36530 May 2012.  PMID: 22590557  PMCID: PMC3349715
  5. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.  An animal model of MYC-driven medulloblastoma.  Cancer Cell.  21(2):155-167 Feb 2012.  PMID: 22340590  PMCID: PMC3285431
  6. Dellon ES, Bower JJ, Keku TO, Chen L, Miller CR, Woosley JT, Orlando RC, Shaheen NJ.  Markers of tyrosine kinase activity in eosinophilic esophagitis: A pilot study of the FIP1L1-PDGFRα fusion gene, pERK 1/2, and pSTAT5.  Diseases of the Esophagus.  25(2):166-174 Feb 2012.  PMID: 21819482  PMCID: PMC3213309


  1. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR*, Anders CK*.  Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.  Breast Cancer Research.  13(6):R125 Dec 2011.  *Co-senior authors.  PMID: 22132754  PMCID: PMC3326567
  2. Ang MK, Patel MR, Yin XY, Sundaram S, Fritchie K, Zhao N, Liu Y, Freemerman AJ, Wilkerson MD, Walter V, Weissler MC, Shockley WW, Couch ME, Zanation AM, Hackman T, Chera BS, Harris SL, Miller CR, Thorne LB, Hayward MC, Funkhouser WK, Olshan AF, Shores CG, Makowski L, Hayes DN.  High XRCC1 expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.  Clinical Cancer Research.  17(20):6542-6552 Oct 2011.  PMID: 21908577  PMCID: PMC3725262
  3. Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM, Der CJ.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.  Small GTPases.  2(4):202-210 Jul 2011.  PMID: 22145092  PMCID: PMC3225909
  4. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA.  The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.  Cancer.  117(8):1602-1611 Apr 2011.  PMID: 21472708  PMCID: PMC4265570
  5. Vitucci M, Hayes DN, Miller CR.  Gene expression profiling of gliomas:  Merging genomic and histopathological classification for personalised therapy.  British Journal of Cancer.  104(4):545-553 Feb 2011.  PMID: 21119666  PMCID: PMC3049580
  6. Dellon ES, Chen X, Miller CR, Fritchie KJ,  Rubinas TC, Woosley JT, Shaheen NJ.  Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease.  American Journal of Gastroenterology.  106(2):264-271 Feb 2011.  PMID: 20978486  PMCID: PMC4372242
  7. Horbinski C, Miller CR, Perry A.  Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade.  Brain Pathology.  21(1):57-73 Jan 2011.  PMID: 21129060


  1. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WF, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes DN.  Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.  Clinical Cancer Research.  16(19):4864-4875 Oct 2010.  PMID 20643781  PMCID: PMC2953768
  2. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and Cancer Genome Atlas Research Network.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.  Cancer Cell.  17(1):98-110 Jan 2010.  PMID: 20129251  PMCID: PMC2818769


  1. Goodgame B, Viswanathan A, Zoole J, Gao F, Miller CR, Subramanian J, Meyers BF, Patterson GA, Govindan R.  Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients.  Journal of Thoracic Oncology.  4(11):1370-1374 Nov 2009.  PMID: 19692932
  2. Perry A, Miller CR, Gujrati M, Scheithauer BW, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK.  Malignant gliomas with primitive neuroectodermal tumor-like components: A clinicopathologic and genetic study of 53 cases.  Brain Pathology.  19(1):81-90 Jan 2009.  PMID: 18452568
  3. Buchsbaum DJ, Miller CR,McNally LR, Kaliberov SA.  Cancer gene therapy.  In: Oldham RK and Dillman RO (eds), Principles of Cancer Biotherapy, 5th Ed., Dordrecht: Kluwer, 2009.  Chapter 19: Pages 589-612.  ISBN 978-90-481-2277-6.
  4. Miller CR, Karpinich NO, Zhang Q, Bullitt E, Kozlov S, and Van Dyke T.  Modeling astrocytomas in a family of inducible genetically engineered mice: implications for preclinical cancer drug development.  In: Van Meir EG (ed), CNS Cancer, Models, Prognostic Factors, and Targets, 1stEd., Cambridge: Springer, 2009.  Chapter 7: Pages 119-145.  ISBN 978-1-60327-552-1.


  1. Yu J, Miller R, Zhang W, Sharma M, Holtschlag V, Watson MA, McLeod HL.  Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.  Pharmacogenomics. 9(10):1459-1466 Oct 2008.  PMID: 18855534  PMCID: PMC2575840
  2. Trembath D, Miller CR, Perry A.  Grey zones in brain tumor classification:  Evolving concepts.  Advances in Anatomic Pathology 15(5):287-297 Sep 2008.  PMID: 18724102
  3. Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R.  A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.  American Journal of Clinical Oncology.  31(1):22-28 Feb 2008.  PMID: 18376223


  1. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL.  PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.  Oncology Reports.  17(4):853-857 Apr 2007.  PMID: 17342327
  2. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM.  Tissue transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.  Oncogene 26(18):2563-2573 Apr 2007.  PMID: 17099729
  3. Miller CR and Perry A.  Glioblastoma:  Morphological and molecular genetic diversity.  Archives of Pathology and Laboratory Medicine 131(3):397-406 Mar 2007.  PMID: 17516742
  4. Miller CR and McLeod HL.  Pharmacogenomics of cancer chemotherapy-induced toxicity.  Journal of Supportive Oncology 5(1):9-14 Jan 2007.  PMID: 17265780
  5. Vadivelu S, Mangano FT, Miller CR, Leonard JR.  Multifocal Langerhans cell histiocytosis of the pediatric spine:  a case report and literature review.  Child’s nervous system.  23(1)127-131 Jan 2007.  PMID: 17021733


  1. Miller CR, Dunham C, Scheithauer B, Perry A.  Significance of necrosis in grading of oligodendroglial neoplasms:  A clinicopathological and genetic study of newly diagnosed high-grade gliomas.  Journal of Clinical Oncology.  24(34):5419-5426 Dec 2006.  PMID: 17135643


  1. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J.  Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.  Cancer Gene Therapy 12(3):284-294 Mar 2005.  PMID: 15650766


  1. Miller CR andPerry A.  Immunohistochemical differentiation of hemangioblastoma from metastatic clear cell renal carcinoma: An update.  Advances in Anatomic Pathology 11(6):325 Nov 2004.
  2. Miller CR andPerry A.  CD34 and MAP-2 immunohistochemistry in the differential diagnosis of epilepsy-associated glioneuronal tumors.  Advances in Anatomic Pathology 11(6):326 Nov 2004.


  1. Buchsbaum DJ, Miller CR, Mahasreshti P, Curiel DT.  Cancer gene therapy.  In: Oldham RK (ed), Principles of Cancer Biotherapy, 4th Ed., Dordrecht: Kluwer, 2003.  Chapter 19: Pages 583-613.  ISBN 1-4020-0706-X.


  1. Blanquicett C,Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation.  Molecular Cancer Therapeutics 1(12):1139-1145 Oct 2002.  PMID: 12481438
  2. Gustin A, Pederson L, Miller R, Chan C, Vickers SM.  Application of molecular biology studies to gene therapy treatment strategies.  World Journal of Surgery 26(7):854-860 Apr 2002.  PMID: 11960211
  3. Miller CR,Williams CR,Buchsbaum DJ, Gillespie GY.  Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.  Cancer Research 62(3):773-780 Feb 2002.  PMID: 11830532
  4. Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in vitro.  Analytical Biochemistry 301(2):189-199 Feb 2002.  PMID: 11814289


  1. Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT.  Selectivity of TAG-72 targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.  Clinical Cancer Research 6(11):4323-4233 Nov 2000.  PMID: 11106250


  1. BlackwellJL, Miller CR, Douglas JT, Li H, Reynolds PN, Carroll WR, Peters GE, Strong TV, Curiel DT.  Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.  Archives of Otolaryngology, Head & Neck Surgery 125(8):856-863 Aug 1999.  PMID: 10448731
  2. Miller CR.  Targeted adenovirus vectors.  Science & Medicine 6(5):18-19 Sep/Oct 1999.
  3. Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT.  A system for the propagation of adenoviral vectors with genetically modified receptor specificities.  Nature Biotechnology 17(5):470-475 May 1999.  PMID: 10331807


  1. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.  Cancer Research 58(24):5738-5748 Dec 1998.  PMID: 9865732
  2. Reynolds PN, Miller CR, Goldman CK, Doukas J, Sosnowski BA, Rogers BE, Gomez-Navarro J, Pierce GF, Curiel DT, Douglas JT.  Targeting adenoviral infection with basic fibroblast growth factor enhances gene delivery to vascular endothelial and smooth muscle cells.  Tumor Targeting 3(3):156-164 Dec 1998.
  3. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT.  An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology 72(12):9706-9713 Dec 1998.  PMID: 9811704  PMCID: PMC110480
  4. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, CurielDT.Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.  Journal of Virology 72(3):1844-1852 Mar 1998.  PMID: 9499035  PMCID: PMC109474


  1. Sevilla CL, Mahle NH, Eliezer N, Uzieblo A, O’Hara SM, Nokubo M, Miller R, Rouzer CA, Marnett LJ. Development of monoclonal antibodies to the malondialdehyde-deoxyguanosine adduct, pyrimidopurinone.  Chemical Research in Toxicology 10(2):172-180 Feb 1997.  PMID: 9043428


  1. Ebbinghaus SW, Vigneswaran N, Miller CR, Chee-Awai RA, Mayfield CA, Curiel DT, Miller DM.  Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes.  Gene Therapy 3(4):287-297 Apr 1996.  PMID: 8732160
  2. Miller R, Curiel DT.  Towards the use of replicative adenoviral vectors for cancer gene therapy.  Gene Therapy 3(7):557-559 Jul 1996.  PMID: 8818641
UAB the University of Alabama at Birmingham home
UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.